Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,186,690
  • Shares Outstanding, K 222,860
  • Annual Sales, $ 3,551 M
  • Annual Income, $ 443,300 K
  • 36-Month Beta 0.84
  • Price/Sales 7.82
  • Price/Cash Flow 15.51
  • Price/Book 3.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 1.60
  • Number of Estimates 7
  • High Estimate 1.77
  • Low Estimate 1.47
  • Prior Year 1.28
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
115.40 +11.36%
on 09/07/18
130.49 -1.52%
on 09/24/18
+11.01 (+9.37%)
since 08/24/18
3-Month
114.40 +12.33%
on 08/16/18
138.77 -7.39%
on 07/26/18
+0.94 (+0.74%)
since 06/22/18
52-Week
102.10 +25.87%
on 04/20/18
144.91 -11.32%
on 10/17/17
-14.31 (-10.02%)
since 09/22/17

Most Recent Stories

More News
Alexion Announces Successful Phase 3 PREVENT Study of Soliris(R) (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

-- Safety Profile Consistent with that Seen in Previous Studies and Real-World Use --

ALXN : 128.51 (+5.34%)
Alexion Pharm Rises 2.27% on Heavy Volume: Watch For Potential Pullback

Alexion Pharm (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $117.57 to a high of $120.63. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of...

ALXN : 128.51 (+5.34%)
Look for Shares of Alexion Pharm to Potentially Rebound after Yesterday's 2.47% Sell Off

Alexion Pharm (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $118.57 to a high of $121.78. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $119.84...

ALXN : 128.51 (+5.34%)
Alexion to Present at Citi's 13th Annual Biotech Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Citi's 13th Annual Biotech Conference in Boston, MA on Thursday, September 6, 2018 at 8:15 a.m., EDT....

ALXN : 128.51 (+5.34%)
Watch for Alexion Pharm to Potentially Pullback After Gaining 2.47% Yesterday

Alexion Pharm (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $119.85 to a high of $123.38. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of...

ALXN : 128.51 (+5.34%)
Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco

The biotech sector witnesses a pretty low key week with a handful of regulatory updates. Regeneron secures an FDA approval for the label expansion of its key drug Eylea.

VRTX : 182.17 (+1.16%)
ALNY : 93.26 (-1.39%)
TEVA : 23.86 (-2.05%)
REGN : 390.19 (-0.02%)
ALXN : 128.51 (+5.34%)
Alexion's BLA for ALXN1210 Gets Priority Review From FDA

The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.

LGND : 268.34 (+3.27%)
ILMN : 358.25 (+0.03%)
GILD : 75.62 (+0.15%)
ALXN : 128.51 (+5.34%)
Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More

Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More

FOXA : 45.01 (+1.53%)
MA : 221.35 (-0.25%)
SCHW : 51.56 (-0.54%)
FTV : 86.33 (-0.75%)
ABBV : 93.42 (+1.26%)
ALXN : 128.51 (+5.34%)
Biotech ETFs in Focus on String of Q2 Earnings Beat

Biotech ETFs draw attention post impressive Q2 results.

IBB : 119.96 (+1.19%)
FBT : 156.67 (+2.11%)
BBH : 133.40 (+0.82%)
IEIH : 27.15 (+0.04%)
GILD : 75.62 (+0.15%)
AMGN : 207.21 (+1.03%)
ALXN : 128.51 (+5.34%)
BIIB : 347.02 (+0.47%)
Biotech ETFs in Focus on String of Q2 Earnings Beat

Biotech ETFs draw attention post impressive Q2 results.

IBB : 119.96 (+1.19%)
FBT : 156.67 (+2.11%)
BBH : 133.40 (+0.82%)
IEIH : 27.15 (+0.04%)
GILD : 75.62 (+0.15%)
AMGN : 207.21 (+1.03%)
ALXN : 128.51 (+5.34%)
BIIB : 347.02 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ALXN with:

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

See More

Key Turning Points

2nd Resistance Point 133.07
1st Resistance Point 130.79
Last Price 128.51
1st Support Level 125.93
2nd Support Level 123.35

See More

52-Week High 144.91
Fibonacci 61.8% 128.56
Last Price 128.51
Fibonacci 50% 123.51
Fibonacci 38.2% 118.45
52-Week Low 102.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar